Atorvastatin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Dyslipidemias

Conditions

Dyslipidemias

Trial Timeline

Oct 1, 2007 → May 1, 2008

NCT ID

NCT00540293

About Atorvastatin

Atorvastatin is a approved stage product being developed by Pfizer for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT00540293. Target conditions include Dyslipidemias.

What happened to similar drugs?

5 of 5 similar drugs in Dyslipidemias were approved

Approved (5) Terminated (0) Active (0)

✅Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved

✅Atorvastatin + AtorvastatinPfizerApproved

✅AtorvastatinPfizerApproved

✅Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01186289	Pre-clinical	Withdrawn	Oct 1, 2010	Oct 1, 2012	Neurocognitive Dysfunction
NCT00993915	Pre-clinical	Completed	Apr 1, 2010	Dec 1, 2011	Cardiovascular Diseases
NCT00827606	Phase 3	Completed	Mar 1, 2009	Oct 1, 2013	Familial Hypercholesterolemia
NCT00772564	Approved	Completed	Aug 1, 2008	Aug 1, 2010	Myocardial Infarction
NCT00917644	Approved	Completed	Jul 1, 2008	Sep 1, 2008	Hypercholesterolemia
NCT00540293	Approved	Completed	Oct 1, 2007	May 1, 2008	Dyslipidemias
NCT00576576	Pre-clinical	Completed	Jul 1, 2007	Mar 1, 2010	Atherosclerosis
NCT00432354	Phase 2/3	UNKNOWN	Mar 1, 2007	Mar 1, 2009	Systemic Lupus Erythematosus
NCT00172419	Pre-clinical	Completed	Mar 1, 2007	Dec 1, 2008	Hyperlipidemia
NCT00441597	Approved	Completed	Feb 1, 2007	Mar 1, 2009	Ischemia Reperfusion Injury
NCT00343655	Phase 3	Terminated	Jan 1, 2007	Aug 1, 2007	Cardiovascular Diseases
NCT00640744	Approved	UNKNOWN	Feb 1, 2006	Feb 1, 2010	Atherosclerosis
NCT00136942	Phase 3	Completed	Apr 1, 2005	—	Hyperlipidemia
NCT01785615	Phase 1/2	Completed	Nov 1, 2004	May 1, 2013	Metabolic Syndrome
NCT00150371	Phase 3	Completed	Jun 1, 2004	May 1, 2005	Hypercholesterolemia
NCT00644709	Approved	Completed	Sep 1, 2003	Mar 1, 2005	Dyslipidemias
NCT00163150	Approved	Completed	Jun 1, 2003	Feb 1, 2006	Cerebrovascular Accident
NCT00151502	Phase 3	Completed	Nov 1, 2002	Jul 1, 2007	Alzheimer's Disease
NCT00163202	Approved	Completed	Jun 1, 2002	Aug 1, 2005	Coronary Arteriosclerosis
NCT00124397	Approved	Completed	Jul 1, 2001	Dec 1, 2004	Type 2 Diabetes Mellitus

Competing Products

15 competing products in Dyslipidemias

See all competitors

Product	Company	Stage	Hype Score
LY3202328 + Placebo + Atorvastatin + Simvastatin	Eli Lilly	Phase 1	29
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg	Yuhan	Approved	43
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC	Eli Lilly	Phase 1	29
LY3885125 + Placebo	Eli Lilly	Phase 1	21
LY3561774 + Placebo	Eli Lilly	Phase 1	29
LY3561774 + Placebo	Eli Lilly	Phase 2	35
LY2484595 + Placebo + Atorvastatin	Eli Lilly	Phase 2	35
Atorvastatin + Atorvastatin	Pfizer	Approved	43
Atorvastatin	Pfizer	Approved	43
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	43
Vupanorsen + Placebo	Pfizer	Phase 2	35
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	43
GWP42003 + GWP42003 + GWP42004 + Placebo	Jazz Pharmaceuticals	Phase 2	32
ARO-APOC3	Arrowhead Pharmaceuticals	Phase 2	32
ARO-ANG3 + sterile normal saline (0.9% NaCl)	Arrowhead Pharmaceuticals	Phase 1	26